BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Lifted by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 16.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,338,062 shares of the biotechnology company’s stock after buying an additional 481,359 shares during the quarter. Fisher Asset Management LLC owned 1.61% of BioCryst Pharmaceuticals worth $25,369,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares in the last quarter. Xponance Inc. boosted its stake in BioCryst Pharmaceuticals by 13.1% during the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 1,505 shares in the last quarter. Creative Planning boosted its stake in BioCryst Pharmaceuticals by 5.9% during the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock valued at $375,000 after buying an additional 2,734 shares in the last quarter. CWM LLC boosted its stake in BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,772 shares in the last quarter. Finally, Diversified Trust Co boosted its stake in BioCryst Pharmaceuticals by 18.0% during the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 3,774 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Barclays raised their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. JMP Securities increased their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Trading Up 0.1 %

Shares of BioCryst Pharmaceuticals stock opened at $7.50 on Thursday. The stock has a 50-day moving average price of $7.63 and a 200 day moving average price of $7.27. The company has a market cap of $1.55 billion, a P/E ratio of -12.29 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. The firm’s revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.19) earnings per share. On average, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.